DocGo Inc. (DCGO) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -800%. A quarter ago, it was expected that this company would post earnings of $0.04 per share when it actually produced earnings of $0.04, delivering no surprise.Over the last four quarters, the company has surpassed conse ...

DocGo (DCGO) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Good afternoon, ladies and gentlemen, and welcome to the DocGo First Quarter Earnings Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on a Thursday, 05/08/2025. I would now like to turn the conference over to Mike Cole, VP of Investor Relations. Please go ahead. Speaker1 Thank you, operator. Before turning the call over ...

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR For the transition period from to Commission File Number: 001-39618 DocGo Inc. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 85-2515483 | | --- | --- ...

Exhibit 99.1 DocGo Announces First Quarter 2025 Results Company Focuses on Growing Medical Transportation and Payer & Provider Businesses, Navigates Municipal Uncertainty and Migrant Services Transition Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, May 8 , 2025 – DocGo Inc. (Nasdaq: DCGO) ("DocGo" or the "Company"), a leading provider of technology- enabled mobile health and medical transportation services, today announced financial and operating results for the ...

Core Insights - Kahn Swick & Foti, LLC (KSF) is investigating DocGo Inc. following allegations of misrepresentation regarding its contracts and executive conduct [1][2] - DocGo's contract with U.S. Customs and Border Protection (CBP) was reported to be worth under $2 billion, contrary to the company's claim of $4 billion [2] - The CEO of DocGo resigned due to fabricated elements of his educational background [2] - A securities class action lawsuit has been filed against DocGo and its executives for failing to disclose material information and violating federal securities laws [3] - The court has denied DocGo's motion to dismiss the lawsuit, allowing it to proceed [3] - KSF's investigation is focused on potential breaches of fiduciary duties by DocGo's officers and directors [3] Company Overview - DocGo is a healthcare company that provides medical transportation and mobile health services in the U.S. and the U.K. [2] - The company is currently facing legal challenges due to allegations of corporate misconduct [3] Legal Context - KSF is a prominent securities litigation law firm, ranked among the top 10 firms nationally based on total settlement value [4] - The firm is seeking information from individuals who may assist in the investigation or have been long-term holders of DocGo shares [4]

Group 1 - DocGo (DCGO) reported Q4 '24 results on February 28th, leading to a share price decline of over 20%, with a total drop of more than 45% from its peak in mid-February of this year [1] - The company has faced scrutiny regarding its corporate governance and compliance practices, which may have contributed to the negative market reaction [1] Group 2 - The analysis emphasizes the importance of understanding regulatory governance and corporate compliance in evaluating the company's performance and potential investment opportunities [1]

Core Viewpoint - DocGo Inc. (DCGO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][10]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of stocks, leading to price movements based on their buying or selling actions [4]. Motion Acquisition's Earnings Outlook - The upgrade for Motion Acquisition reflects an improvement in its earnings outlook, which could positively affect its stock price [3][5]. - For the fiscal year ending December 2025, Motion Acquisition is expected to earn $0.10 per share, representing a 60% decrease from the previous year, but the Zacks Consensus Estimate has increased by 18.8% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [7]. - The upgrade of Motion Acquisition to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $120.8 million, a 39% decrease from $199.2 million in Q4 2023 [32] - For the full year, revenues were $616.6 million in 2024, down 1% from 2023 [34] - Net loss for Q4 2024 was $7.6 million, compared to net income of $8 million in Q4 2023 [35] - Adjusted EBITDA for Q4 2024 was $1.1 million, down from $22.6 million in the previous year [35] - Adjusted EBITDA for the full year was $60.3 million, a 12% increase from $54 million in 2023 [36] Business Line Data and Key Metrics Changes - Mobile Health revenue for Q4 2024 was $71.8 million, down 52% from Q4 2023 [34] - Medical transportation revenue increased to $49.1 million in Q4 2024, up about 1% from Q4 2023 [34] - Transportation revenues for 2024 were 7% higher than in 2023, with a compound annual growth rate of 32% over the past three years [34] Market Data and Key Metrics Changes - The company provided services across 31 states in the U.S. and the UK, facilitating over 1.5 million patient interactions in 2024 [13] - The company was recognized as one of the top innovators in healthcare, receiving over 40,000 job applications from healthcare clinicians and corporate staff [14] Company Strategy and Development Direction - The company aims to build a 100-year company that transforms healthcare delivery and provides high-quality, accessible care [10] - Investments are being made in technology, experienced operators, and sales personnel to support growth [11] - The company acquired PTI Health, a mobile phlebotomy company, to expand its service capabilities [20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a near-term impact on profitability due to aggressive investments but sees strong growth potential in the future [10] - The company anticipates a significant cash flow tailwind from accounts receivable related to migrant programs, expected to be fully paid by mid-2025 [22] - Management expressed confidence in achieving a 15% annual revenue growth expectation for 2025 and beyond [34] Other Important Information - SG&A as a percentage of total revenues was 39.7% in Q4 2024, up from 27.6% in Q4 2023 [38] - The company generated $70.3 million in cash flow from operations in 2024, a significant turnaround from a negative cash flow in 2023 [42] Q&A Session Summary Question: What is the 2025 revenue guidance considering the migrant revenue situation? - Management indicated that the migrant revenue could be less than the previously expected $50 million, but they are transitioning personnel to growing base business revenues [51][113] Question: Can you provide details on the $3.2 million of unanticipated expenses? - Management explained that being self-insured introduces uncertainty in expenses, but they are working on better reserving practices to mitigate future fluctuations [72][75] Question: What is the status of the municipal business and Project Prime initiative? - Management confirmed that Project Prime is progressing well, with contracts signed to provide services for existing contractors to municipal entities [121]

DocGo, Inc (NASDAQ:DCGO) Q4 2024 Results Conference Call February 27, 2025 5:00 PM ET Company Participants Mike Cole - VP of Investor Relations Lee Bienstock - Chief Executive Officer Norman Rosenberg - Chief Financial Officer Conference Call Participants Pito Chickering - Deutsche Bank Richard Close - Canaccord Genuity David Larsen - BTIG Aidan Conniff - Stifel Operator Good afternoon, ladies and gentlemen, and welcome to the DocGo Fourth Quarter and Full Year 2024 Earnings Call. At this time, all lines ar ...

分组1 - DocGo Inc. reported quarterly earnings of $0.05 per share, exceeding the Zacks Consensus Estimate of $0.04 per share, but down from $0.06 per share a year ago, representing a 25% earnings surprise [1] - Over the last four quarters, Motion Acquisition has surpassed consensus EPS estimates two times, with revenues of $120.83 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 6.02% [2] - The stock of Motion Acquisition has declined approximately 4.3% since the beginning of the year, while the S&P 500 has gained 1.3% [3] 分组2 - The earnings outlook for Motion Acquisition is mixed, with a current consensus EPS estimate of $0.01 on $107.89 million in revenues for the coming quarter and $0.08 on $407.34 million in revenues for the current fiscal year [7] - The Medical Services industry, which includes Motion Acquisition, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Surgery Partners, is expected to report quarterly earnings of $0.38 per share, reflecting a year-over-year decline of 13.6%, with revenues projected to be $828.84 million, up 12.7% from the previous year [9][10]